The recent and unexpected occurrence of patients with the development of skin lesions on the hands and/ or feet has been described recently. As these cases occurred contemporaneously with the Coronavirus Disease 2019 (COVID-19) and as it was the most often occurrence of de novo frostbites, the question raised of whether there is a direct link between the occurrence of these lesions and infection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the responsible for CoVID-19. Indeed, mechanisms of these lesions and the precise correlation with Sars-CoV-2 remains poorly understood. Therefore, this study aim to: 1. Determine the possible link with this virus, 2. Understand the mechanisms involved in the pathogenesis of these lesions.
In this study, the investigator designed a prospective interventional study in order to
collect blood samples and skin lesion biopsy at significant time points in patients who
present a skin lesion. The intervention in this study is limited to some blood samples and
skin biopsies.
Two 7 mL tubes of blood will be collected at consultant time for essentially serological test
for the SARS-CoV-2 and for analysing certain populations of white blood cells. The second
additional blood sample of 7 mL will be collected around day 15 after inclusion in a dry tube
to perform a serological test for SARS-CoV-2 at a distance from the onset of skin signs.
A biopsy for histological study is usually done in patients with acrosyndrome. This is why
this type of biopsy will be done as a routine care of these patients. An immunohistochemical
study could complete the histological explorations using an anti-coronavirus antibody if
arguments in favour of SARS-CoV-2 are demonstrated. In this study, patients who accept and
sign informed consent will be proposed a skin biopsy on a characteristic lesion for freezing.
This biopsy can be used for transcriptomic analysis. This may allow a better understanding of
the mechanisms of the disease.
Other: Blood sampling
Recruited patients will be subjected to 2 blood samples of 7 mL at day 0 for serological analysis and cell collection and to an additional blood sample of 7 mL at day 15 for serological analysis
Other: Skin biopsy
Recruited patients will be subjected to a single skin biopsy at day 0 for histological and transcriptomic analysis
Inclusion Criteria:
- Adult patients
- Consultant for the recent occurrence of lesions on the fingers and or toes
- Having signed an informed consent
- Affiliated or entitled to a social security regime
Exclusion Criteria:
- Patients under guardianship or under curate
- Patients under state medical assistance
Department of Dermatology, Tarnier hospital, AP-HP
Paris, France
Investigator: Sélim Aractingi, MD, PhD
Contact: +33158411813
selim.aractingi@aphp.fr
Sélim Aractingi, MD, PhD
+33158411813
selim.aractingi@aphp.fr
Marie Benhammani-Godard
00.33158411190
marie.godard@aphp.fr